Table 2.
C-index and AUC table demonstrate that AJCC8 has a higher prognostic value than AJCC7 for stage III patients, while it remains the same for stage I and II patients
| Stage | Recurrence (%) | RFS C-index (95% CI) |
5-year RFS AUC (95% CI) |
Death No. (%) | OS C-index (95% CI) |
5-y OS AUC (95% CI) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AJCC7 | AJCC8 | P * | AJCC7 | AJCC8 | AJCC7 | AJCC8 | P * | AJCC7 | AJCC8 | |||
| Stage I | 63 (6.8) | 0.63 (0.56 to 0.69) | 0.56 (0.49 to 0.63) | .07 | 0.63 (0.55 to 0.70) | 0.55 (0.47 to 0.62) | 38 (4.3) | 0.48 (0.38 to 0.58) | 0.48 (0.41 to 0.56) | .90 | 0.55 (0.43 to 0.67) | 0.54 (0.46 to 0.63) |
| Stage II | 60 (33.5) | 0.65 (0.57 to 0.72) | 0.65 (0.57 to 0.72) | .83 | 0.68 (0.58 to 0.78) | 0.68 (0.57 to 0.78) | 28 (15.6) | 0.61 (0.50 to 0.72) | 0.61 (0.50 to 0.72) | .17 | 0.60 (0.47 to 0.74) | 0.60 (0.47 to 0.74) |
| Stage III | 89 (62.2) | 0.65 (0.60 to 0.70) | 0.70 (0.66 to 0.75) | .01 | 0.63 (0.50 to 0.77) | 0.70 (0.57 to 0.83) | 52 (36.4) | 0.69 (0.63 to 0.76) | 0.72 (0.66 to 0.78) | .27 | 0.74 (0.65 to 0.84) | 0.76 (0.67 to 0.84) |
*
A two-sided nonparametric test was used to calculate P values. AJCC7 = American Joint Committee on Cancer Staging Manual Seventh Edition; AJCC8 = American Joint Committee on Cancer Staging Manual Eighth Edition; AUC = area under the curve; CI = confidence interval; C-index = concordance index; OS = overall survival; RFS = recurrence-free survival.